A faster treatment for tuberculosis? TB Alliance launches pivotal trial for four-drug regimen
Combining some of the latest breakthroughs in tuberculosis research with some of the oldest treatment options, the TB Alliance has launched a pivotal trial to test how well their four-drug regimen can treat tuberculosis in light of growing resistance to current therapies.
The not-for-profit is contributing an experimental compound, pretomanid, which represents a class of novel anti-bacterial agents called nitroimidazole. The rest of the regimen calls for J&J’s bedaquiline — perhaps better known as Sirturo — the off-patent antibiotic moxifloxacin, and pyrazinamide, a generic med often found in TB combos.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.